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Abstract 
Extracellular vesicles (ECVs) are a novel route of inter-cellular communication along the 
nephron, with the potential to change the function of the recipient cell. However, it is not 
known whether this is a regulated process analogous to other signalling systems. Here we 
report that desmopressin, an analogue of the hormone vasopressin, stimulated 
fluorescently-loaded ECV uptake into a kidney collecting duct cell line (mCCDC11) and into 
primary cells. To confirm uptake of biologically active ECVs we exposed mCCDC11 cells to 
ECVs isolated from cells over-expressing the microRNA miR-503. In these cells, miR-503 
target gene expression was down-regulated, but only in the presence of desmopressin. 
Mechanistically, ECV entry into mCCDC11 cells required cyclic AMP production, was reduced 
by inhibiting dynamin, and was selective for ECVs from kidney tubular cells. To establish in 
vivo relevance we measured the urinary excretion and tissue uptake of fluorescently-loaded 
ECVs delivered systemically to mice before and after administration of the V2 receptor 
antagonist, tolvaptan. Basally, 2.5% of ECVs were recovered in the urine; tolvaptan 
increased recovery 5-fold and reduced ECV deposition in kidney tissue. Furthermore, in a 
patient with central diabetes insipidus, desmopressin reduced the excretion of ECVs derived 
from glomerular and proximal tubular cells. These data are consistent with vasopressin-
regulated uptake of ECVs in vivo. We conclude that ECV uptake is a specific and regulated 
process. Physiologically, ECVs are a new mechanism of inter-cellular communication; 
therapeutically, ECVs represent a vehicle by which RNA therapy could be targeted to 
specific cells for the treatment of kidney disease.   
Word count: 250/250 
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Introduction 
Most, if not all, cell types release membrane-bound vesicles which can be isolated from 
biofluids such as blood1, saliva2 and urine.3 These extra-cellular vesicles (ECVs) are 
heterogeneous, but can be broadly classed as being derived directly from the cell membrane 
or originating from intra-cellular pathways. Cell membrane derived ECVs include 
microparticles and apoptotic bodies. Classically, exosomes are distinguished from other 
ECV sub-populations by their unique biogenesis in the intra-cellular endosomal pathway 
following fusion of the multi-vesicular body with the limiting plasma membrane. These intra-
cellular vesicles are termed exosomes after release into the extra-cellular space.  
 
Conventionally, ECVs were viewed as a removal system for senescent or excess lipid and 
protein from cells.4 Their cargo changes with cell injury and disease, so ECVs represent a 
potential reservoir for biomarker discovery, even a noninvasive replacement for tissue 
biopsy.5 However, this promise has not yet been translated into a biomarker with real-life 
clinical utility. Research has identified a potential role in inter-cellular signalling - ECVs can 
deliver functional protein and RNA from one cell to another in vitro.6 The mechanisms by 
which target cells internalise ECVs are yet to be fully elucidated and whether ECV transfer 
between cells occurs in vivo is still to be unequivocally confirmed. In cell culture studies, 
ECV uptake by cells has been reported via a number of mechanisms including clathrin-
dependent endocytosis, caveolae-dependent endocytosis, phagocytosis and 
macropinocytosis.7 However, it is not established whether ECV uptake by recipient cells is a 
physiologically regulated process and, if it is, which pathways or hormones are involved. 
 
Urine contains ECVs originating from the circulation and from cells that line the urinary tract.3 
These ECVs maintain urine sterility by virtue of their antibacterial activity.8 The most studied 
urinary ECV sub-type are exosomes, which are derived from the kidney’s glomerulus and all 
regions of the nephron. Urinary exosomes contain protein, messenger RNA (mRNA), 
microRNA and mitochondrial DNA that originates from kidney tubular cells.3,9 Given the 
unidirectional flow of urine along the nephron, the kidney is anatomically designed for 
potential ECV transfer from proximal to distal nephron segments. In the kidney there is 
evidence of ECV signaling: exosomes from injured tubular cells transfer mRNA into 
fibroblasts resulting in cell activation and stem cell-derived exosomes protect against acute 
kidney injury by transfer of RNA.10,11 Using aquaporin (AQP) membrane water channels to 
track ECV signaling we previously demonstrated ECV-mediated AQP transfer from 
stimulated to unstimulated collecting duct cells.12 
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Using a kidney collecting duct cell line (mCCDC11), which responds robustly to aldosterone 
and vasopressin stimulation by transporting sodium and water, respectively, we have 
established and characterised a model of ECV release. These ECVs are exosome-like in 
their properties: they express archetypal exosomal proteins, such as tumor susceptibility 
gene 101 (TSG101), which localise to a density on a sucrose gradient that is characteristic 
of exosomes.13 Transmission electron microscopy (TEM) and nanoparticle tracking analysis 
(NTA) confirm that this collecting duct cell line releases ECVs of exosome size and shape 
that express surface exosomal markers.12,14 We have previously demonstrated that 
vasopressin, a pituitary neuropeptide that regulates water homeostasis, modulates the 
aquaporin 2 (AQP2) content of these ECVs in vitro and this regulation translates into rodent 
models and humans.12,14 The aim of the present study was to investigate the role of 
vasopressin in the regulation of ECV uptake into the kidney collecting duct. 
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Results 
Vasopressin stimulates ECV uptake by mCCDC11 and primary collecting duct cells   
ECVs of exosomal size were present in the supernatant from the mCCDC11 cells, as we have 
previously reported (supplementary figure 1). Release of ECVs from mCCDC11 cells was 
significantly increased following stimulation with the vasopressin analogue, desmopressin 
(supplementary figure 2). When the size distribution of ECVs was analysed by NTA the 
increase in ECV release induced by desmopressin corrresponded to release of ECVs in the 
size range 20-100nm, an exosomal size distribution. NTA is a light scatter microscopy 
method of tracking micro- and nanoparticles based on direct and real-time tracking of the 
particles’ Brownian movement, which results in a description of the particle size and 
concentration distribution in a given solution. NTA can be used to count and size specific 
subgroups of nanoparticles using fluorescent antibodies against surface proteins, including 
ECVs derived from kidney cells in culture and in urine.14 mCCDC11 cell ECVs were 
successfully loaded with fluorescent Cell Tracker label and membrane disruption with QIAzol 
cell lysis reagent substantially reduced the NTA signal, consistent with fluorescent loading of 
membrane-bound ECVs (supplementary figure 3). Cell Tracker nanocrystals in PBS 
without any ECVs produced no NTA signal.  
 
ECV uptake by mCCDC11 cells was quantified by tracking fluorescence and by the cellular 
response to microRNA-loaded ECVs – two complementary approaches that report physical 
uptake and biological activity, respectively. ECVs, harvested from mCCDC11 cells and loaded 
with fluorescent nanocrystals (Cell Tracker label), were applied to different mCCDC11 cells 
grown in a confluent monolayer. Entry of ECVs into the recipient cell was observed under 
fluorescent microscopy (figure 1), the percentage of fluorescent cells was determined by 
FACS analysis and the concentration of ECVs remaining in the supernatant was measured 
by NTA. Incubation of the recipient cells with the vasopressin analogue, desmopressin, 
caused a time-dependent increase in the proportion of fluorescent cells (figures 1 and 
2A&B). Significant ECV uptake occurred after 48 hours of desmopressin stimulation; shorter 
exposure times had no effect (figure 2A). This is comparable to the time course of 
desmopressin-induced ECV release (supplementary figure 2) and AQP2 expression in this 
cell line.12 At concentrations similar to the physiological concentration of vasopressin,15 96 
hours of desmopressin incubation approximately doubled the proportion of recipient cells 
taking up fluorescent ECVs (figure 2C). Consistent with this, the concentration of 
fluorescently-loaded ECVs remaining in the supernatant was significantly reduced by 
treatment with desmopressin (figure 2D). Tolvaptan; a selective V2 receptor antagonist, 
abolished the increase in ECV uptake induced by desmopressin (figure 2E), while OPC-
21268, a V1 antagonist had no effect (desmopressin stimulated mCCDC11 cells 23.2±5.2% vs 
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desmopressin stimulated cells treated with OPC-21268 (1µM) 18.8±1.4%, n=3, p=0.5). 
Endothelin-1, a peptide which inhibits sodium transport in the collecting duct,16 had no effect 
on ECV uptake by mCCDC11 cells when applied alone, but physiologically antagonised the 
effect of desmopressin (figure 2F).  
 
To complement and confirm the data from fluorescence-based ECV tracking we utilised 
ECVs loaded with a specific microRNA and used cellular target mRNA suppression as the 
readout of functional ECV uptake. ECVs were harvested from a human umbilical vein 
endothelial cell (HUVEC) line transduced to over-express miR-50318 and a control cell 
HUVEC line. This cell line was chosen as the mRNA targets of miR-503 are well-
described.18,19 The expression of miR-503 in the isolated ECV pellet was confirmed by qPCR 
(overexpressing Ct value 26.6 vs control Ct value >35). ECVs from both cell lines were 
added to unstimulated or desmopressin-stimulated mCCDC11 cells . Target genes influenced 
by miR-503 have been identified: we measured the mRNA expression of VEGF-A, FGF2, 
CDC25A and CCNE1. ECVs containing miR-503 induced a significant down-regulation of 
the target genes following desmopressin stimulation (figure 3). In the absence of 
desmopressin there was no significant change in gene expression.  
 
Building on these data from our collecting duct cell line, ECV uptake was visualised by 
fluorescence microscopy in rat primary collecting duct cells to determine whether ECV 
uptake was also regulated by the vasopressin system in native cells. We isolated cells 
expressing AQP2 from whole rat kidney (figure 4). There was uptake of ECVs into these 
cells, but only in the presence of desmopressin (3.16ng/ml for 2 hours) (figure 4). 
 
cAMP and dynamin mediate desmopressin-induced ECV uptake  
The V2 receptor is coupled with Gs proteins and causes activation of the cAMP pathway.15 
Inhibition of cAMP-dependent protein kinase A (PKA) with H-89 prevented the increase in 
uptake of fluorescent ECVs following desmopressin stimulation (figure 5A). Stimulation of 
mCCDC11 cells with forskolin increased uptake of fluorescent ECVs independent of 
desmopressin stimulation (figure 5B). Endocytosis can be cAMP dependent20 and, taken 
together with previous studies showing that ECVs enter cells through the endocytotic 
pathway7, we investigated the role of dynamin, a GTPase that mediates endocytosis. 
Dynasore, a non-competitive inhibitor of dynamin activity21,22, significantly reduced 
desmopressin-stimulated ECV uptake to a level below that of control cells (figure 5C). In 
combination, these data indicate that basal and desmopressin-induced uptake of ECVs 
requires cAMP activation and dynamin activity. 
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ECV uptake by mCCDC11 cells  is selective for ECV cell of origin 
Next, we determined whether ECVs derived from different cell types are also internalised 
under vasopressin regulation. We incubated mCCDC11 cells (without and with desmopressin 
stimulation) with equal numbers of ECVs (1 x 108 / mL) harvested from the following renal 
cell types: mCCDC11 cells (mouse); proximal tubule (HK2 - human); and juxtaglomerular 
(RG1 - mouse). The ECVs from all cell types had similar size distributions, as quantified by 
NTA (figure 6A). Treating recipient mCCDC11 cells with desmopressin increased uptake of 
the proximal tubule and collecting duct-derived ECVs but not of those from juxtaglomerular 
cells (figure 6B). This tubular cell selectivity was confirmed by NTA analysis, which 
demonstrated decreased proximal and collecting duct ECVs in the mCCDC11 cell culture 
supernatant, but no change in ECVs from juxtaglomerular cells (figure 6C).  
 
The V2 receptor is expressed on the basolateral membrane of the renal principal cell. 
Therefore we examined ECV uptake in mCCDC11 cells polarised by growing on transwell 
plates and stimulated with desmopressin on either the apical or basolateral side. Basolateral 
desmopressin stimulated uptake of apically applied ECVs, whereas desmopressin applied to 
the apical membrane had no effect (figure 6D).  
 
Vasopressin regulates urinary ECV excretion in mice and humans 
As a control, mice were intravenously injected with ECV-free Cell Tracker nanocrystals in 
solution and there was no signal detected in their urine by NTA. Mice were intravenously 
injected with fluorescently-loaded ECVs derived from mCCDC11 cells . The urinary excretion 
of these fluorescent ECVs was measured by NTA. QIAzol treatment of the urine 
substantially reduced the number of particles measured by NTA which is consistent with the 
presence of fluorescently-loaded membrane bound ECVs (supplementary figure 4). 
 
Mice were then administered either tolvaptan, furosemide or vehicle (control) followed by a 
second injection of the same number of ECVs. Urine output increased 1.3 fold following 
tolvaptan and furosemide dose. In the control group, 2.5±1.0% and 1.8±0.7% of the 
systemically injected ECVs were recovered in the urine after the first and second ECV dose, 
respectively. In a separate group of mice, tolvaptan treatment increased the ECV excretion 
from 1.1±0.7% to 13.5±3.9%, consistent with inhibition of vasopressin-mediated ECV uptake 
(figure 7A) Treatment with furosemide produced no change in ECV excretion.  
 
Kidney, liver and spleen tissue was examined by fluorescence microscopy after systemic 
injection of fluorescently-loaded ECVs without and with tolvaptan pre-treatment (figure 8). In 
the absence of tolvaptan ECVs were clearly present in kidney tissue (and liver and spleen). 
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After tolvaptan treatment there was a substantial reduction in ECV number in kidney, without 
an obvious effect on ECV deposition in liver and spleen (figure 8). 
 
As an additional in vivo proof-of-concept study, the urinary excretion of nephron segment 
specific ECVs was measured in a patient with central diabetes insipidus using NTA 
combined with Qdot labelled antibodies for segment specific proteins.14 Following self-
directed desmopressin intra-nasal administration, there was a decrease in both glomerular 
(podocalyxin-like) and proximal tubular (cubilin) protein-expressing ECVs (figure 7B). This is 
consistent with our cell and mouse data and supports the presence of desmopressin-
regulated uptake of glomerular and proximal tubule ECVs by distal segments of the nephron 
in humans. 
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Discussion  
Extra-cellular vesicles (ECVs) transfer protein and RNA between cells to alter the phenotype 
of the recipient cell in vitro. Our data demonstrate that ECV uptake by recipient cells is 
hormonally regulated by vasopressin in kidney cell culture, mice and humans. We also 
demonstrate that ECVs can, by vasopressin-regulated transfer of microRNA, change gene 
expression profiles in the recipient mCCDC11 cell. The renal tubular system is ideally suited to 
exploit this mechanism of cell-to-cell communication, which opens up a new paradigm for 
physiological cross-talk between nephron segments. Moreover, ECVs offer a vehicle for 
targeting RNA therapies to diseased kidney tubular cells. 
 
Vasopressin is released from the posterior pituitary in response to an elevation in blood 
osmolality. Its principal role is to stimulate water reabsorption by the renal collecting duct. 
This is achieved through activation of the V2 receptor on the basolateral membrane of renal 
principal cells which, via a cAMP/PKA cascade, phosphorylates the water channel AQP2 
permitting trafficking to the apical cell membrane from sub-apical recycling endosomes. In 
parallel, vasopressin stimulates endocytosis of vesicles from the cellular plasma membrane 
to maintain membrane equilibrium.  In this paper, we demonstrate a new role for vasopressin 
as a hormonal regulator of ECV uptake in cells, mice and humans. In cell culture studies we 
used 4 complementary read-outs of ECV uptake – fluorescent microscopy, flow cytometry 
and microRNA transfer into cells, combined with NTA of ECVs remaining in the culture 
medium. The data generated by these different methodologies consistently demonstrated 
that desmopressin stimulated ECV uptake into mCCDC11 cells and primary collecting duct 
cells. The time course of ECV uptake was different: mCCDC11 cells needed 48h of 
desmopressin stimulation before significant uptake was recorded, similar to the time-frame 
required before desmopressin stimulates AQP2 expression and ECV release in these cells; 
by contrast, primary cells responded within 2h of exposure. One explanation for the different 
response times is that naïve mCCDC11 cells require new protein production for uptake of 
ECVs, but this remains speculative. The uptake mechanism was V2 receptor-mediated and 
cAMP/PKA dependent, in keeping with the established physiological pathway that increases 
water uptake. In our cell model, desmopressin-induced ECV uptake was reduced by 
endothelin-1, suggesting that ECV uptake is under opposing physiological regulation by 
vasopressin and endothelin-1. This is consistent with data that indicate endothelin-1, via the 
ETB receptor, antagonizes the physiological actions of vasopressin in the collecting duct 
both in vitro17 and in vivo.16 Thus, the mechanism of vasopressin-induced ECV uptake is 
consistent with the known physiology of this hormone and is likely to be a consequence of 
hormone-induced plasma membrane endocytosis. Hormonal regulation of ECV entry into 
cells has not been demonstrated in any cell line and we also found that vasopressin 
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stimulated ECV (likely exosome) release from mCCDC11 cells. It is not yet clear how this up-
take and release fits into a cell signalling paradigm and it is even possible that ECVs taken 
up from the tubular lumen could be re-released. Nevertheless, that both processes were 
influenced by vasopressin indicates that ECV inter-cellular signalling may be a tightly 
regulated physiological process.  
 
There has been a substantial increase in publications on the biology of ECVs, particularly 
relating to their signalling potential. However, in the kidney and other organs there is little 
evidence that regulated signalling occurs in vivo. To test whether vasopressin is important 
for renal ECV uptake and excretion in vivo we injected fluorescently-loaded ECVs 
systemically into mice. After injection these ECVs appeared in urine and kidney tissue which 
is consistent with previous published studies23 and important for two reasons. First, 
investigators performing proteomic and transcriptomic analysis of urinary ECVs cannot 
assume that new biomarkers have originated from the kidney, and urinary non-renal ECVs 
may offer a non-invasive way to assess the physiology and pathology on other (non-renal) 
organs. Second, the presence of plasma-derived ECVs in urine provides proof-of-concept 
that systemically administered novel therapeutic interventions, delivered within ECVs, could 
gain access to renal tubules. The mechanism of systemic ECV entry into urine remains to be 
determined and a greater understanding may allow ECV manipulation to increase their 
urinary excretion. We also demonstrated that tolvaptan, a selective V2 receptor antagonist, 
substantially increased the urinary excretion of systemically administered ECVs and reduced 
the number of ECVs present in kidney tissue. Furosemide had no effect despite increasing 
urine output, which strongly suggests that the increased excretion of ECVs following 
tolvaptan treatment was not due to the increased urine output per se.  These are the first 
data that demonstrate vasopressin is a regulator of urinary ECV excretion and confirms that 
our findings in cells translate to mice. Combining antibodies to nephron segment-specific 
proteins with NTA can identify the cellular origin of urinary ECVs. We collected urine from a 
patient with central diabetes insipidus – a condition defined by lack of vasopressin - and 
determined the effect of intra-nasal desmopressin on glomerular and proximal tubule derived 
ECVs. Following desmopressin, the urinary concentration of these ECVs fell, which is 
consistent with vasopressin regulation of urinary ECV excretion in humans. While these 
human data are hypothesis-generating, they are entirely consistent with the data from cells 
and mice. A limitation is that the concentration of urinary creatinine changed as a result of 
desmopressin treatment making the normalisation of spot urine ECV numbers a challenge. 
In the future larger validation studies should be performed to confirm our human data. We 
conclude that kidney collecting duct cells, under the control of vasopressin, actively modify 
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the population of ECVs in the urine. This is an important concept and must be accounted for 
in preclinical and clinical analysis of urinary ECV profiles.  
 
Urine contains ECVs from multiple cell types outside and within the urinary tract. The 
collecting duct, at the distal end of the tubular urine flow, is therefore exposed to ECVs from 
multiple cell types, which express a wide range of surface proteins. Intriguingly, uptake by 
our mCCDC11 cell line was selective with regard to the ECV cell of origin. Proximal tubular 
ECVs (HK2 cells) and mCCDC11 cell ECVs were internalised under desmopressin regulation. 
By contrast, uptake of ECVs derived from the kidney juxtaglomerular cell (RG1) was not 
desmopressin-sensitive, despite this being a mouse cell line. This observation was 
confirmed by flow cytometry of the cells and NTA of the supernatant. The ECVs were of a 
similar size profile, suggesting that the selectivity of vasopressin-regulated uptake is based 
on surface molecules within the ECV, such as proteins. Physiologically, the collecting duct 
would be exposed to proximal tubular ECVs in greater number than ECVs derived from 
juxtaglomerular cells and selective uptake may augment proximal to distal tubular signalling. 
Therapeutically, such selectivity could be a major advantage for harnessing ECVs as a drug 
delivery system, permitting precision targeting of therapy to treat segment-specific renal 
tubular disorders.  
 
The cargo of ECVs includes proteins, mitochondrial DNA and RNA from their cell of origin. 
Across a range of cell types it has been reported that ECVs can transfer microRNA into a 
recipient cell and this can result in modulation of target mRNA. We utilised ECVs that 
contain miR-503 to demonstrate that desmopressin stimulation results in decreased target 
mRNA expression in mCCDC11 cells . Urinary ECVs contain multiple RNA species so there is 
clear potential for signalling both within the kidney and from other organs to kidney tubular 
cells. However, recent reports have introduced a note of caution; Chevillet et al.24 reported 
that the content of microRNA in naturally occurring ECVs is very low. Nevertheless, the 
therapeutic potential of ECVs is high. Our data suggest that ECVs injected intravenously can 
freely enter urine and could be engineered to deliver a complex package of RNA and protein 
that simultaneously targets multiple steps in an intra-cellular disease pathway.19 These 
ECVs could be targeted to specific kidney cell types by manipulation of their surface markers 
and by hormonal activation of target cells.  
 
In conclusion, the uptake of ECVs by kidney collecting duct cells is regulated by vasopressin 
via intra-cellular pathways that also mediate the increase in water permeability. Vasopressin 
regulation occurs in cell lines, primary cells, mice and possibly humans. This regulated 
uptake of ECVs can result in intra-cellular modulation of target mRNA species. 
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Physiologically, ECVs are a fundamental new mechanism of inter-cellular communication; 
therapeutically, ECVs represent a novel vehicle by which RNA therapy can be targeted to 
specific cells for the treatment of kidney disease. 
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Methods: 
Cell Culture 
The murine cell line (mCCDC11) was a kind gift from Hans-Peter Gaeggeler and Bernard 
Rossier (University of Lausanne, Lausanne, Switzerland)25 and was grown as per Street et 
al.12 Briefly, mCCDC11 cells were grown in Dulbecco’s modified Eagles medium (DMEM)–F12 
medium, 1:1 (Gibco, Paisley, UK), supplemented with 2% fetal calf serum (FCS; Invitrogen, 
Paisley, UK), 1× insulin transferrin selenium (ITS) solution (Gibco), 100 IU/ml penicillin and 
100μg/ml streptomycin (Invitrogen, Paisley, UK), 50 pM dexamethasone (Sigma Aldrich, 
Gillingham, UK), 1 nM 3,3,5-triiodo-L-thyronine sodium salt (Sigma Aldrich) and 10 ng/ml 
epidermal growth factor (Sigma Aldrich). Passaging was achieved by two 10 min washes 
with 1 mM EDTA in Dulbecco’s modified phosphate-buffered saline (DPBS) followed by 
incubation in trypsin EDTA solution (Lonza, Basel, Switzerland). The presence of ECVs in 
FCS would interfere with our study so, after confluency, cells were washed twice in DPBS 
and grown in serum-free media.  
 
For the different cell type experiments, we used ECVs isolated from the supernatant of HK2 
and RG1 cell lines. The HK2 cell line was a kind gift from Dr Kenneth Simpson (University of 
Edinburgh, United Kingdom). HK2 cells were grown following the same described method as 
for mCCDC11 cells . The RG1 cell line was grown by supplementing 1:1 DMEM/F12 (Gibco) 
with 10 % heat-inactivated FCS, IFN-γ (Peprotech, London, UK) at 100 µg/ml, and 1 % ITS 
containing 1 mg/ml insulin, 0.55 ml/ml human transferrin and 0.5 µg/ml sodium selenite 
(Gibco, Paisley, UK). 1X glutamine, 1X penicillin/streptomycin (pen/strep, Life Technologies) 
and 1X antioxidants (Sigma Aldrich) were added to this, as well as 10µM Y-27632 (Tocris, 
Bristol, UK) and filtered. The cell culture supernatant was removed from either cell type at 
70-80% confluency of the cell layer.    
 
Human umbilical vein ECs (HUVECs) and human microvascular ECs (HMVECs) (both from 
Lonza) were grown in EGM-2 (EBM-2 medium supplemented with growth factors) and 2% 
fetal bovine serum (FBS) (Lonza). Lipofectamine RNAiMAX (Life Technologies) was used to 
transfect HUVECs with pre-miR-503 or pre-miR-control (50nM final concentration) according 
to the manufacturer's instructions. 
 
Primary cortical collecting duct isolation 
Male rat kidneys were placed in DMEM/Ham’s F12 medium with Glutamax (Gibco) 
containing 10% foetal bovine serum (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Gibco). After the peri-renal fat was removed, the kidneys were decapsulated and the cortex 
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macroscopically dissected. The cortex was incubated in serum-free isolation medium 
containing 1mg/ml collagenase I and IV (Sigma Aldrich) for 45 minutes at 37°C. The 
resultant solution was ground and serially sieved to a final filter size of 40µm. The filtered 
solution was centrifuged at 27 000g through a 48% Percoll gradient (Sigma Aldrich) and the 
highest band of 3-4 distinct bands was carefully removed. The matter contained within this 
band was washed, sieved and the cells were resuspended in DMEM/Hams’s F12 media with 
glutamax containing: 5 µg/ml insulin, 50 nM dexamethasone, 10 ng/ml epidermal growth 
factor, 5 µg/ml transferrin, 30 nM sodium selenite, 10 nM triiodothyronine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 25 mM NaHCO3 and 10% FBS. The suspension was 
plated onto collagen-coated 35-mm tissue culture dishes (Corning) and maintained in an 
incubator under humidified 5% CO2 atmosphere at 37°C.  
 
Isolation and fluorescent loading of ECVs  
Culture medium from the cells was vigorously vortexed then centrifuged at 15,000 x g for 10 
min to pellet any cells, large membrane fragments and other debris. The supernatant was 
then centrifuged at 200,000 x g for 60 min to pellet ECVs. The pellet was washed with 
phosphate-buffered saline (PBS) and then re-centrifuged at 200,000 x g for 60 min before 
final suspension in PBS.12 
 
Pelleted ECVs were loaded with Cell Tracker 655 (Invitrogen) following the manufacturer’s 
protocol. Briefly, pelleted ECVs were incubated with the Cell Tracker 655 conjugate in 200ul 
fresh serum-free culture media for 1hour at 37°C. These labelled ECVs were washed with 
fresh media before being put back on confluent cells.  
 
Collecting duct cell stimulation 
Desmopressin (Sigma Aldrich) was added as per Street et al.12 For short periods of 
stimulation, desmopressin and fluorescently-loaded ECVs were added together for 1-8 
hours. With longer time periods of cell stimulation (24-96 hours), for the final 24 hours of 
stimulation fluorescent ECVs were added. At the end of the study the supernatant was 
collected for NTA analysis and cells removed by trypsinisation (as described previously12) for 
flow cytometry. In addition to desmopressin, in specific experiments for the final 24 hours the 
cells were treated with tolvaptan (10nM) (Sigma Aldrich), endothelin-1 (10pM) (Sigma 
Aldrich) or H-89 (25µM) (Sigma Aldrich).26 Treatment with the Dynamin Inhibitor I (Dynasore 
(150uM): Sigma Aldrich) was for 45 minutes immediately prior to ECV addition, as per 
published studies.22 Cells were treated with 10µM forskolin from Coleus forskohlii (Sigma 
Aldrich) and incubated with fluorescent ECVs overnight.27,28 To polarise the mCCDC11 cells 
they were cultured on the polyester membrane of Transwell inserts (Corning Costar Co, 
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USA) at a high density to allow the cells to be confluent within three days. Desmopressin 
was added to the top or bottom Transwell chamber for 48 hours then fluorescent ECVs were 
added left to incubate for the final 24 hours of the 96 hour period. 
 
Particle size and concentration distribution measurement with NTA  
As per our published method14, ECVs were analysed using the NanoSight LM 10 instrument 
(NanoSight Ltd, Amesbury, UK). The analysis settings were optimised and kept constant 
between samples and each video was analysed to give the mean, mode, median and 
estimated concentration for each particle size. All experiments were carried out at a 1:1000 
dilution, yielding particle concentrations in the region of 1x108 particles/ml in accordance with 
the manufacturer’s recommendations. All samples were analysed in triplicate. For 
fluorescent NTA analysis a 532nm (green) laser diode excited the fluorescent loaded ECVs 
with a long pass filter (430nm). 
 
For urine studies fluorescent labelling with antibody conjugated to Quantum dots was used 
with NTA. Anti-CD24 antibody was a kind gift of Dr. P. Altevogt, German Cancer Research 
Center, Heidelberg, Germany. Mouse anti-cubilin and anti-podocalyxin-like protein antibody 
was purchased from Abcam (Cambridge, UK) and Millipore (Billerica, MA, USA), 
respectively. Following the manufacturer’s protocol, Qdots were conjugated to antibodies 
with a Qdot 605 Antibody Conjugation Kit (Invitrogen). For fluorescent NTA analysis a 
532nm (green) laser diode excited the Qdots with a long pass filter (430nm) so that only 
fluorescent particles were tracked and labelled particle concentration determined by NTA 
software.  
 
Flow cytometry for total cell fluorescence 
Total cell fluorescence was measured by flow cytometry on a 5LSR Fortessa cytometer (BD 
Biosciences, Oxford, UK). Cells were briefly stained with 1µM DAPI nucleus stain (Sigma 
Aldrich) and having been exposed to Cell Tracker 655 (Invitrogen) labelled ECVs as 
described, was excited with a violet laser (405 nm) and emission detected using 450/50 and 
630/70 band pass filters respectively. Gates were set using unstained cells and cells stained 
with DAPI alone. Flow cytometry data were analysed with FloJo LLC software version 8 
(FlowJo LLC, Oregon, USA) and the results are presented as the percentage of total 
fluorescent cells.   
 
Fluorescence microscopy  
Using control and desmopressin-stimulated cells grown on a cover slip in a 35mm glass-
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bottom dish or fixed mouse tissue, internalisation of labelled ECVs with DAPI stained 
mCCDC11 cell nuclei and Phalloidin stained cell membranes (Sigma Aldrich) or AQP2 
fluorescent antibodies (Merck Millipore, USA) was visualised by an Olympus AX-70 Provis 
epifluorescence microscope equipped with a Hamamatsu Orca II CCD camera. Images were 
collected with a 60 x oil immersion objective lens and acquired by using mDaemon software 
(Zenn, Manchester, UK). Each picture was acquired with laser intensities and amplifier gains 
adjusted to avoid pixel saturation and analysed using Adobe Photoshop CC 2014 (Adobe 
Systems, San Jose, California). 
 
Transmission electron microscopy of mCCDC11 cell culture supernatant was performed as 
previously described (2). 
 
RNA extraction and quantitative real time analysis 
Total RNA was extracted using miReasy kit (Qiagen, Venlo, Netherlands). Real-time 
quantification to measure microRNAs was performed with the TaqMan microRNA reverse 
transcription kit and microRNA assay  
(miR-503) (Applied Biosystems, Life Technologies) with Lightcycler 480 (Roche Diagnostics, 
Penzberg, Germany). SYBR qPCR was used to measure vascular endothelial growth-factor 
A (VEGF-A), fibroblast growth factor-2 (FGF2), cell division cycle 25A (CDC25A), cyclin-1E 
(CCNE1) and 18S rRNA. Primers are pre-designed from Sigma (KiCqStartTM Primers). Each 
reaction was performed in triplicate. Quantification was performed by the 2∆∆Ct method.29 
 
Animals 
All experiments were conducted in accordance with UK Home Office regulations and the 
Animals (Scientific Procedures) Act 1986. Wild type (C57BL6/J and CD1) mice were sex and 
age matched across experiments. General anaesthesia was induced by intra-peritoneal 
injection of 100mg/kg thiobutabarbital sodium and venous access gained via the jugular 
vein. Urine flow was maintained throughout with a 0.9% saline infusion (0.2mL/10gbw/hour 
i.v). A bolus of cell tracker labelled ECVs from mCCDC11 cells was injected in a final volume 
of 0.1ml (i.v.). Urine was collected via a urinary catheter for 2 hours following injection. The 
injection of ECVs was repeated without or with preceding tolvaptan administration (0.3mg/kg 
i.v) or furosemide (1mg/kg, i.v.).  
 
Clinical case study 
Repeated urine samples were obtained from a 16-year-old male with stable central diabetes 
insipidus (CDI) secondary to a craniopharyngioma, who was being routinely treated with 
daily desmopressin (dDAVP nasal spray; 0.1ml (10mcg) desmopressin acetate per spray). 
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The CDI patient samples were initially stored at 4°C then frozen at -80 °C. Analysis of the 
CDI patient samples were performed by a researcher blinded to the timing of desmopressin 
treatment. The protocol was agreed by the institutional ethical review body and informed 
consent was obtained. 
 
Statistical analysis 
Unless otherwise indicated, analyses were performed on data generated from triplicate 
results. Data were analysed using GraphPad Prism Version 6 (GraphPad Software, La Jolla, 
CA, USA). From the NTA data, the area under the curve (AUC) was determined following 
the trapezoidal rule for particles sized 20-100nm. Flow cytometry data were analysed using 
FloJo LLC, version 8 (FloJo LLC) gating around the main cell population. Total cell 
fluorescence was determined as the median of single cells lying in a gate defined 
proportioned from the unstained control, in a forward scatter vs. side scatter dot plot, 
expressed as percentage total cell fluorescence. Non-parametric Kolmogorov-Smirnov t 
tests and ANOVAs were used to determine significant differences between different 
conditions. A value of p < 0.05 was the level of nominal significance. 
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Legends 
Figure 1. Fluorescent microscopy of unstimulated (left) and desmopressin-stimulated 
(3.16ng/ml for 96 hours - right) mCCDC11 cells incubated with fluorescently loaded ECVs 
(red). Desmopressin stimulated ECV uptake into the cellular cytoplasm. DAPI-stained nuclei 
(blue),  cell membrane stained with phalloidin (green). 
Figure 2. ECV uptake by mCCDC11 cells is increased by desmopressin stimulation. A.) Flow 
cytometry data demonstrating no significant fluorescently-loaded ECV uptake following 
desmopressin stimulation (3.16ng/ml) for up to 8 hours (n=3).  Fluorescent cells expressed 
as % of total cell number. B.) Flow cytometry data demonstrating ECV uptake following 
longer desmopressin stimulation. (n=3, * p < 0.05: 3.16ng/ml desmopressin stimulation vs no 
stimulation). C.) Desmopressin (3.16ng/ml for 96 hours) stimulated mCCDC11 cells had 
significantly increased fluorescence after incubation with labelled ECVs. Fluorescent cells 
expressed as % of total cell number (n=5).  D.) NTA analyses of fluorescently-loaded ECVs 
in the cell culture supernatant from control and desmopressin (3.16ng/ml for 96 hours) 
stimulated cells presented as the area under the concentration curve (AUC) for particles 
sized between 20-100nm (n=5). Desmopressin stimulation reduced the concentration of 
ECVs in the supernatant. E.) Fluorescence of control and desmopressin stimulated cells 
(3.16ng/ml for 96 hours) exposed to fluorescently-loaded ECVs in the absence and presence 
of tolvaptan (10nM). Fluorescent cells expressed as % of total cell number (n=5). F.) 
Fluorescence of control and desmopressin stimulated cells (3.16ng/ml for 96 hours) exposed 
to fluorescently-loaded ECVs in the absence and presence of endothelin-1 (10pg/mL). 
Fluorescent cells expressed as % of total cell number (n=5).   Figures C-F are Tukey plots 
(bottom and top of the box are the first and third quartiles, and the band inside is the median. 
The whiskers are the lowest datum still within 1.5 IQR of the lower quartile and the highest 
datum still within 1.5 IQR of the upper quartile). * p < 0.05. 
Figure 3. ECVs deliver functional microRNA into desmopressin-stimulated mCCDC11 cells. 
Change in gene expression when desmopressin stimulation (3.16ng/ml for 96 hours) is 
compared to unstimulated cells in the absence of ECVs, with control HUVEC derived ECVs 
or with miR-503 loaded ECVs. A.) vascular endothelial growth factor-A (VEGF-A), B.) 
fibroblast growth-factor 2 (FGF2), C.) cyclin E-1 (CCNE1) and D.) cell division cycle 25A 
(CDC25A). Values are expressed as the difference between Ct values in unstimulated cells 
– Ct values in desmopressin stimulated cells with 18S as endogenous control. Negative 
values indicate down-regulation and positive values indicate up-regulation of target genes by 
desmopressin without or with the stated ECVs. n=9, * p < 0.05. All plots are Tukey plots.  
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Figure 4. Rat primary collecting duct cells take up ECVs after desmopressin stimulation. The 
cells express AQP2 protein (green), as detected by fluorescent antibody labelling. 
Fluorescently loaded ECVs (red) enter primary cells with desmopressin (3.16ng/ml for 2 
hours) treatment. DAPI-stained nuclei are blue.   
 
Figure 5. ECV uptake by mCCDC11 cells following desmopressin stimulation is mediated by 
cAMP and dynamin activity. A.) Desmopressin (3.16ng/ml for 96 hours) stimulated ECV 
uptake which was decreased by PKA inhibition (H-89 – 25µM) of the cAMP pathway. B.) 
ECV uptake was increased by cAMP stimulation through forskolin (10µM). C.)  Dynasore 
(150nM) inhibition of dynamin activity decreased ECV uptake by desmopressin stimulated 
cells below that of the control cells. In figures A-C: fluorescent cells expressed as % of total 
cell number. n= 6 * p <0.05. All plots are Tukey plots.  
 
Figure 6. Cell type specificity for ECV uptake A.) NTA measurement of ECVs from different 
cell types prior to incubation with mCCDC11 cells. CCD = collecting duct, HK2 = proximal 
tubule and RG1 = juxtaglomerular cell derived B.) Comparing total cell fluorescence between 
control and desmopressin (3.16ng/ml for 96 hours) stimulated mCCDC11 cells following 
labelled ECV incubation from 3 cell types: mCCDC11 cells (CCD), HK2 (human proximal 
tubular cell line) and RG1 (murine juxtaglomerular cell line). 1 x 108/mL ECVs were added to 
all experiments (n=6. * p < 0.05). C.) NTA analyses of cell culture supernatant incubated with 
different cell type derived ECVs (mCCDC11, HK2 and RG1) from control and desmopressin 
(3.16ng/ml for 96 hours) stimulated cells presented as the area under the concentration 
curve (AUC) for particles sized between 20-100nm. Desmopressin stimulation reduced the 
concentration of mCCDC11 and HK2 ECVs in the supernatant but not in cells incubated with 
RG1 ECVs D.) Polarised cells take up ECVs under desmopressin regulation. Total cell 
fluorescence of polarised mCCDC11 cells stimulated with desmopressin (3.16ng/ml for 96 
hours) either apically or basolaterally compared to unstimulated cells. Labelled ECVs were 
applied to apical compartment of Transwell (n=3. * p < 0.05). Figure B-D are Tukey plots.  
 
Figure 7. Vasopressin V2 receptor regulates urinary ECV excretion in mice and humans.  
A.) Urinary excretion of systemically adminstered ECVs in mice. Group 1 – control group; 
urine ECV excretion following 2 i.v. injections of fluorescently-loaded ECVs. Group 2 – urine 
ECV excretion after 2 i.v. injections of labelled ECVs. Between injections mice were treated 
with tolvaptan (0.3mg/kg). n=5 per group, * p < 0.05. Group 3 – urine ECV excretion after 2 
i.v. injections of labelled ECVs. Between injections mice were treated with furosemide 
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(1mg/kg, n=4). ECV excretion expressed as percentage of the total number of injected ECVs 
excreted in the urine. Data expressed as a Tukey plot. B.) 24 hour ECV excretion by a 
patient with central diabetes insipidus.  Lines represent the time of desmopressin treatment 
(dashed line) and concentration of ECVs expressing nephron-segment specific proteins: 
glomerular (podocalyxin-like protein, PODX-L), proximal tubular (cubilin), and CD24 (pan-
segment urinary ECV marker). ECV urine concentration measured by NTA and normalised 
by urinary creatinine concentration. All data are expressed as mean±SD. NTA 
measurements were taken in triplicate for each time point. 
 
Figure 8. Tissue distribution of fluorescently-loaded ECVs systemically injected into mice 
without and with tolvaptan pre-treatment. After IV injection of ECVs mouse organs were 
harvested 1 hour later. Red = ECVs, blue = DAPI, green = AQP2. Without tolvaptan red 
signal is present in kidney tissue. With tolvaptan (0.3mg/kg) pretreatment the red signal is 
reduced. ECVs are present in liver and spleen without and with tolvaptan. Bar, 20µm. 
 
Supplementary figure 1. Structures of exosome size and shape are visible in the mCCDC11 
cell culture medium using transmission electron microscopy. Bar, 100 nm. 
 
Supplementary figure 2. ECVs of exosome size are released from mCCDC11 cells following 
stimulation by desmopressin. A) Number of particles in the supernatant from mCCDC11 cells 
stimulated with desmopressin (3.16ng/ml) for the time indicated. Particles measured by NTA. 
Data are presented as the area under the concentration curve (AUC) for particles sized 
between 20-100nm. n=5. *p=0.02. B) Number of particles in the supernatant from mCCDC11 
cells stimulated with desmopressin (3.16ng/ml) for the time indicated. Particles measured by 
NTA. Data are presented as the area under the concentration curve (AUC) for particles sized 
between 100-500nm. n=5. 
      
	   	  
Supplementary figure 3. Kidney collecting duct cell ECVs were loaded with fluorescent Cell 
Tracker label and had an exosomal size distribution, as measured by NTA (A). Membrane 
disruption with QIAzol cell lysis reagent substantially reduced this NTA signal, consistent 
with fluorescent loading of membrane-bound ECVs (B). 
 
 
Supplementary figure 4. Particles of exosome size are present in mouse urine after 
intravenous injection of fluorescently-loaded ECVs derived from mCCDC11 cells. Treatment of 
the urine with QIAzol cell lysis reagent substantially reduced this NTA signal, consistent with 
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the presence of fluorescently-loaded membrane-bound ECVs. A). NTA trace demonstrating 
particle size and concentration. B) Tukey plot of urine before and after QIAzol treatment. 
Data are presented as the area under the concentration curve (AUC) for particles sized 
between 20-100nm. n=5. *p<0.05. 
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Supplementary figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Structures of exosome size and shape are visible in the 
mCCDC11 cell culture medium using transmission electron microscopy. Bar, 100 nm. 
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Supplementary figure 2 
 
 
 
Supplementary figure 2. ECVs of exosome size are released from mCCDC11 cells 
following stimulation by desmopressin. A) Number of particles in the supernatant 
from mCCDC11 cells stimulated with desmopressin (3.16ng/ml) for the time indicated. 
Particles measured by NTA. Data are presented as the area under the concentration 
curve (AUC) for particles sized between 20-100nm. n=5. *p=0.02. B) Number of 
particles in the supernatant from mCCDC11 cells stimulated with desmopressin 
(3.16ng/ml) for the time indicated. Particles measured by NTA. Data are presented 
as the area under the concentration curve (AUC) for particles sized between 100-
500nm. n=5. 
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Supplementary figure 3 
 
 
 
 
 
 
 
 
 
Supplementary figure 3. Kidney collecting duct cell ECVs were loaded with 
fluorescent Cell Tracker label and had an exosomal size distribution, as measured by 
NTA (A). Membrane disruption with QIAzol cell lysis reagent substantially reduced 
this NTA signal, consistent with fluorescent loading of membrane-bound ECVs (B). 
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Supplementary figure 4 
 
 
 
 
 
 
 
Supplementary figure 4. Particles of exosome size are present in mouse urine after 
intravenous injection of fluorescently-loaded ECVs derived from mCCDC11 cells. 
Treatment of the urine with QIAzol cell lysis reagent substantially reduced this NTA 
signal, consistent with the presence of fluorescently-loaded membrane-bound ECVs. 
A). NTA trace demonstrating particle size and concentration. B) Tukey plot of urine 
before and after QIAzol treatment. Data are presented as the area under the 
concentration curve (AUC) for particles sized between 20-100nm. n=5. *p<0.05. 
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